Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN14 | ISIN: CA24463V1013 | Ticker-Symbol: DTC
Tradegate
23.10.25 | 21:49
0,512 Euro
-1,92 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DEFENCE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DEFENCE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5120,53223.10.
0,0000,00023.10.

Aktuelle News zur DEFENCE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoDefence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025320Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
► Artikel lesen
06.10.Defence Therapeutics Inc.: Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025631Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
► Artikel lesen
DEFENCE THERAPEUTICS Aktie jetzt für 0€ handeln
02.10.Defence Therapeutics Inc: Defence names Lambermon as head of quality, operations33
02.10.Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations450Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
► Artikel lesen
23.09.Defence Therapeutics Inc.: Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin729Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in...
► Artikel lesen
16.09.Defence Therapeutics Inc: Defence Therapeutics appoints Phinney as director36
16.09.Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Amie Phinney as Director579Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in...
► Artikel lesen
16.09.Defence Therapeutics Inc: Defence Therapeutics closes debenture unit financing44
15.09.Defence Therapeutics Inc.: Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000526Montreal, Quebec--(Newsfile Corp. - September 15, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in...
► Artikel lesen
02.09.Defence Therapeutics Inc: Defence Therapeutics hires Phinney as business adviser31
02.09.Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth 1.160Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in...
► Artikel lesen
23.08.Defence Therapeutics Inc: Defence arranges $1.2-million debenture unit offering110
23.08.Defence Therapeutics Inc.: Defence Therapeutics Announces Debenture Units Financing1.166Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...
► Artikel lesen
14.07.Defence Therapeutics Inc: Defence continues Accum ADC, radiopharma programs123
14.07.Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer928Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug...
► Artikel lesen
09.06.Defence Therapeutics Inc: Defence receives USPTO allowance for patent application88
09.06.Defence Therapeutics sichert sich US-Patent für bahnbrechende ADC-Technologie165
09.06.Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology699Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug...
► Artikel lesen
02.06.Defence Therapeutics Inc: Defence Therapeutics opens first U.S. laboratory79
02.06.Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub632Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced...
► Artikel lesen
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,3,15